Your browser doesn't support javascript.
loading
Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary.
Moon, Intae; LoPiccolo, Jaclyn; Baca, Sylvan C; Sholl, Lynette M; Kehl, Kenneth L; Hassett, Michael J; Liu, David; Schrag, Deborah; Gusev, Alexander.
Afiliação
  • Moon I; Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • LoPiccolo J; Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Baca SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Sholl LM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Kehl KL; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Hassett MJ; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Liu D; Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Schrag D; Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Gusev A; Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Nat Med ; 29(8): 2057-2067, 2023 08.
Article em En | MEDLINE | ID: mdl-37550415
ABSTRACT
Cancer of unknown primary (CUP) is a type of cancer that cannot be traced back to its primary site and accounts for 3-5% of all cancers. Established targeted therapies are lacking for CUP, leading to generally poor outcomes. We developed OncoNPC, a machine-learning classifier trained on targeted next-generation sequencing (NGS) data from 36,445 tumors across 22 cancer types from three institutions. Oncology NGS-based primary cancer-type classifier (OncoNPC) achieved a weighted F1 score of 0.942 for high confidence predictions ([Formula see text]) on held-out tumor samples, which made up 65.2% of all the held-out samples. When applied to 971 CUP tumors collected at the Dana-Farber Cancer Institute, OncoNPC predicted primary cancer types with high confidence in 41.2% of the tumors. OncoNPC also identified CUP subgroups with significantly higher polygenic germline risk for the predicted cancer types and with significantly different survival outcomes. Notably, patients with CUP who received first palliative intent treatments concordant with their OncoNPC-predicted cancers had significantly better outcomes (hazard ratio (HR) = 0.348; 95% confidence interval (CI) = 0.210-0.570; P = [Formula see text]). Furthermore, OncoNPC enabled a 2.2-fold increase in patients with CUP who could have received genomically guided therapies. OncoNPC thus provides evidence of distinct CUP subgroups and offers the potential for clinical decision support for managing patients with CUP.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Primárias Desconhecidas Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Primárias Desconhecidas Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos